ArticleNature medicine2018
HIV vaccine candidate activation of hypoxia and the inflammasome in CD14
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 76 citations in OpenAlex.
- Innate immune cell activation after HIV-1 vaccine administration is associated with increased antibody production.Frontiers in immunology · 2024Trial
- Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.The Journal of infectious diseases · 2022Trial
- Preferential engagement of the anti-inflammatory ATP/adenosine axis by HIV vaccine candidate with V1-deleted envelope in male rhesus macaques.Cell reports. Medicine · 2026Article
- Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity.Journal for immunotherapy of cancer · 2025Article
- HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques.Nature communications · 2025Article
- BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs.JCI insight · 2025Article
- Innate immune memory in chronic HIV and HIV-associated neurocognitive disorders (HAND): potential mechanisms and clinical implications.Journal of neurovirology · 2024Review
- Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response.Nature communications · 2024Article
- Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.Viruses · 2024Review
- Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.Frontiers in immunology · 2024Article
- Editorial: Vaccine-induced innate immunity and its role in viral infections.Frontiers in immunology · 2024Article
- Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.PLoS pathogens · 2024Article
- In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4Vaccines · 2023Article
- The NLRP3 inflammasome and gut dysbiosis as a putative link between HIV-1 infection and ischemic stroke.Trends in neurosciences · 2023Review
- ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone.JCI insight · 2023Article
- HIV vaccine candidate plus microbicide decreases SIV infection risk by more than 90.Nature microbiology · 2023Article
- Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques.Nature microbiology · 2023Article
- Human immune and gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity.Communications biology · 2023Article
- Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251.Nature communications · 2023Article
- HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 8 institutions in 2 countries.
Monica VaccariAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Slim FouratiDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-6609-7587
Shari N GordonAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Dallas R BrownAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Massimilano BissaAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Luca SchifanellaAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Isabela Silva de CastroAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Melvin N DosterAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Veronica GalliAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Maria OmslandAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Dai FujikawaAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Giacomo GoriniAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Namal P M LiyanageAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Hung V TrinhUS Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Katherine M McKinnonVaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Kathryn E FouldsVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, MD, USA.
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Richard A KoupVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Marcus P WongDivision of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
Karissa J MunozDivision of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
Johannes S GachDivision of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
Donald N ForthalDivision of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
David C MontefioriDivision of Surgical Sciences, Duke University School of Medicine, Durham, NC, USA.
David J VenzonBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Barbara K FelberHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Margherita RosatiHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
George N PavlakisHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Mangala RaoUS Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Rafick-Pierre SekalyDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Genoveffa FranchiniAnimal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. franchig@mail.nih.gov.
National Cancer Institute · USUniversity of California, Irvine · USDuke University · USNational Institutes of Health · USCase Western Reserve University · USHenry M. Jackson Foundation · USLeidos (United States) · USNational Cancer Institute · UA
Funding
Preventive Vaccines for HIVZIABC011126 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FRANCHINI, GENOVEFFA · 2009 to 2025
$55.3MTesting of Blood Samples for Immune Response and Vaccine ResearchZIAAI005073 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$23.4MHIV/SIV Replication In VivoZIAAI005014 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$22.7MNon-Human Primate CoreZICAI005103 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FOULDS, KATHRYN · 2009 to 2025
$22.7MFunctional And Phenotypic Characterization Of T Cells In ManZIAAI005021 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ROEDERER, MARIO · 2009 to 2022
$14.4MThe role of antibody and the Fc neonatal receptor in transmitted/founder strain selectionR01AI118581 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N · 2015 to 2019
$2.9MCCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261200800001ENIAID NIH HHS R01 AI118581
Abstract
Qualitative differences in the innate and adaptive responses elicited by different HIV vaccine candidates have not been thoroughly investigated. We tested the ability of the Aventis Pasteur live recombinant canarypox vector (ALVAC)-SIV, DNA-SIV and Ad26-SIV vaccine prime modalities together with two ALVAC-SIV + gp120 protein boosts to reduce the risk of SIV
Indexed as
AIDS VaccinesAnimalsAntibody FormationBiomarkersCD4-Positive T-LymphocytesHypoxiaInflammasomesInflammationKiller Cells, NaturalLipopolysaccharide ReceptorsMacaca mulattaMonocytesReceptors, CCR5Risk FactorsSimian Immunodeficiency VirusT-Lymphocytes, Helper-InducerAIDS VaccinesBiomarkersInflammasomesLipopolysaccharide ReceptorsReceptors, CCR5Vaccines, DNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.